Treating to target in psoriatic arthritisCoates, Laura C.Current Opinion in Rheumatology: March 2015 - Volume 27 - Issue 2 - p 107–110 doi: 10.1097/BOR.0000000000000140 EPIDEMIOLOGY AND HEALTH-RELATED SERVICES: Edited by M. Elaine Husni Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review Psoriatic arthritis (PsA) is an inflammatory arthritis causing significant joint damage and impaired quality of life. A treat to target approach has revolutionized the care of patients with rheumatoid arthritis over the last decade. There is now increasing interest in a similar approach in PsA, as it seems that ongoing joint inflammation predicts subsequent damage and loss of function. Recent findings A 2011 European League Against Rheumatism review highlighted a lack of evidence for treat to target in PsA. However, with the development of the minimal disease activity criteria, a target is available and preliminary results from the first randomized treat-to target study (Tight Control of PsA Study) using these criteria have shown significant benefit in joint and skin disease activity and patient-reported outcomes. Summary Early evidence has shown the potential benefit of a treat-to-target approach in PsA and further research is needed to optimize treatment pathways for all subtypes of the disease. NIHR Clinical Lecturer in Rheumatology, Leeds Institute of Rheumatology and Musculoskeletal Medicine, University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK Correspondence to Laura C. Coates, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. Tel: +44 0113 3924961; e-mail: email@example.com Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.